Inclusion Body Myositis (IBM)
Inclusion body myositis is a rare, little known muscle disease, with no effective drug treatment.
Cure IBM is dedicated to inclusion body myositis awareness, education, and research.
Whether you are a patient or a physician, we hope to provide the information you need.
Cure IBM believes it’s time for change!
- Time for increased awareness
- Time for prompt and accurate diagnosis
- Time for research
- Time for treatment and a cure
Inclusion body myositis, sometimes called sporadic inclusion body myositis, causes gradually worsening muscle weakness, usually starting after the age of 40 or 50. Many people slowly progress from normal walking, to using a cane, then a walker, and finally a wheelchair over a time period of about 15 years, although this is extremely variable. Hand function worsens. Many people with IBM eventually become disabled, in some cases losing the ability to move their arms and legs, and also the ability to swallow. The age of onset and the rate of progression vary significantly from patient to patient.
The cause is unknown. The disease is characterized by muscle inflammation and muscle degeneration, but it has not been determined if the inflammation causes the degeneration, or if the degeneration causes the inflammation, or if something else starts the disease process.
Scientists and doctors are studying IBM, but they need more support. The disease is little known and underfunded, even when compared with other rare diseases. We have the tools. Research techniques have improved tremendously. Lack of money is the main obstacle slowing research progress. Now is the time to make a difference!
Introduction to Inclusion Body Myositis
What is IBM? Who gets it? How common is it?
The diagnosis of inclusion body myositis is based on symptoms of muscle weakness, physical exam findings, and several additional tests.
Inclusion body myositis has no generally effective medical therapy, but many things can be done to improve the lives of people with IBM.
The Cure IBM Blog
Negative Results The biotech company Orphazyme announced negative results yesterday for the clinical trial of arimoclomol in the treatment of inclusion body myositis (IBM). The drug failed to meet the primary and secondary endpoints which were used to measure success....
The Orphan Disease Center 2020 Million Dollar Bike Ride Grant Program is offering a $68,245 grant for the study of inclusion body myositis (IBM). Researchers from around the world are eligible to apply. Letters of Interest are due Friday, September 18. The grant is...
JOIN US! On June 13, you can support the cause of inclusion body myositis by biking, walking, running, swimming, or riding in your own town or city. The Million Dollar Bike Ride has become a virtual event this year. Although it is unfortunate that Team Cure IBM cannot...
My Personal Story
Support IBM Research
Join Cure IBM in the fight against Inclusion Body Myositis. Your support will help fund research and the development of treatment options for this debilitating disease.